Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Telisotuzumab Adizutecan

Antibody-drug conjugate · Cytotoxic, directed at c-Met (MET) · developed by AbbVie

Phase 3 Most advanced trial

ABBV Developer

1 Registered trials

What is Telisotuzumab Adizutecan?

Telisotuzumab adizutecan is an antibody-drug conjugate comprising a monoclonal antibody targeting c-Met linked to adizutecan, a topoisomerase inhibitor. The antibody binds c-Met on tumor cells; upon internalization, adizutecan is released to inhibit topoisomerase and induce cell death. It is studied in colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Antibody-drug conjugate
Targets: c-Met (MET), topoisomerase (secondary target)
Mechanism: Cytotoxic, directed at c-Met (MET)
Pathways: DNA replication, tumor angiogenesis
Therapy area: Oncology
Developer: AbbVie (ABBV)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: CVX52RV2DC

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07525206	Phase 3	Colorectal Cancer	Recruiting	ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal Cancer

Other drugs acting on MET

Telisotuzumab Vedotin FDA approved Tepotinib FDA approved Actinium Ac 225 FPI-2068 Phase 1 FPI-2053 Phase 1 Sitravatinib Phase 3 Vebreltinib Phase 1/2

More from AbbVie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Telisotuzumab Adizutecan

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z